STOCK TITAN

Merus to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Merus N.V. announced that its CEO, Bill Lundberg, will participate in two investor conferences: BMO Biopharma Spotlight Series: Oncology Day on November 8 and Stifel 2023 Healthcare Conference on November 14. The BMO conference will have a fireside chat with no live webcast, while the Stifel conference will have a live webcast. Archived presentations will be available on the company's website for a limited time.
Positive
  • None.
Negative
  • None.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

  • BMO Biopharma Spotlight Series: Oncology Day (fireside chat): Wednesday, November 8 at 11:30-11:55 a.m. ET (No live webcast, replay will be available after the event)
  • Stifel 2023 Healthcare Conference (fireside chat): Tuesday, November 14 at 1:15-1:45 p.m. ET (Live webcast available contemporaneously)

Archived presentations will also be available on the Investors page of the Company's website for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Bill Lundberg will participate in the BMO Biopharma Spotlight Series: Oncology Day on Wednesday, November 8.

Bill Lundberg will participate in the Stifel 2023 Healthcare Conference on Tuesday, November 14.

No, there will be no live webcast for the BMO Biopharma Spotlight Series: Oncology Day. However, a replay will be available after the event.

Yes, there will be a live webcast available for the Stifel 2023 Healthcare Conference.

Archived presentations will be available on the Investors page of Merus N.V.'s website for a limited time after the event.
Merus N.V

NASDAQ:MRUS

MRUS Rankings

MRUS Latest News

MRUS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Netherlands
Utrecht

About MRUS

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.